P949: A PHASE 2 TRIAL OF ELRANATAMAB, A B-CELL MATURATION ANTIGEN (BCMA)-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: INITIAL SAFETY RESULTS FOR MAGNETISMM-3. (23rd June 2022) - Lesokhin, A. M.; Arnulf, B.; Niesvizky, R.; Mohty, M.; Bahlis, N. J.; Tomasson, M. H.; Rodrίguez-Otero, P.; Quach, H.; Raje, N. S.; Iida, S.; Raab, M.-S.; Czibere, A.; et al.